Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women.

Uusi-Rasi K, Semanick LM, Zanchetta JR, Bogado CE, Eriksen EF, Sato M, Beck TJ

Bone1 Jun 2005Cited by 106 (Europe PMC)

PMID15878318DOI10.1016/j.bone.2005.03.003PepBankPUB-15878318

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide increased femoral neck bone mass versus placebo, with a dose-related response.
In plain wordsIn women with osteoporosis, teriparatide increased femoral neck bone mass versus placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck bone mass
Study
n = 558
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 or 40 mug once daily · subcutaneous · Median 20 monthsAs given in this study (human).
Source sentences
Summary
At the femoral neck, teriparatide increased bone mass and improved bone geometric strength in both treatment groups compared to the placebo group, with the response being dose-related.
2 context sentences(design, population, supporting numbers)
Summary · context
We evaluated effects of teriparatide (rDNA origin) injection [teriparatide, rhPTH (1-34), TPTD] on hip structure among a subset 558 postmenopausal women enrolled in the Fracture Prevention Trial.
Summary · context
Patients were randomized to once-daily, self-administered subcutaneous injections of placebo (N = 189), teriparatide 20 mug (TPTD20; N = 186), or 40 mug (TPTD40; N = 183) for a median of 20 months.
Report a problemFND-1587831801
02HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide improved femoral neck geometric strength versus placebo, with a dose-related response.
In plain wordsIn women with osteoporosis, teriparatide improved femoral neck geometric strength versus placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck geometric strength
Study
n = 558
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 and 40 mug daily · subcutaneous · Median 20 monthsAs given in this study (human).
Source sentences
Summary
At the femoral neck, teriparatide increased bone mass and improved bone geometric strength in both treatment groups compared to the placebo group, with the response being dose-related.
2 context sentences(design, population, supporting numbers)
Summary · context
We evaluated effects of teriparatide (rDNA origin) injection [teriparatide, rhPTH (1-34), TPTD] on hip structure among a subset 558 postmenopausal women enrolled in the Fracture Prevention Trial.
Summary · context
Patients were randomized to once-daily, self-administered subcutaneous injections of placebo (N = 189), teriparatide 20 mug (TPTD20; N = 186), or 40 mug (TPTD40; N = 183) for a median of 20 months.
Report a problemFND-1587831802
03HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide produced intertrochanteric changes comparable to femoral neck changes, with smaller differences versus placebo.
In plain wordsIn women with osteoporosis, teriparatide improved intertrochanteric structure versus placebo, with smaller differences than at the femoral neck.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseIntertrochanteric structural changes
Study
n = 558
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 and 40 mug daily · subcutaneous · Median 20 monthsAs given in this study (human).
Source sentences
Summary
The changes at the intertrochanteric region were comparable to those at the narrow neck although between-group differences were slightly smaller.
3 context sentences(design, population, supporting numbers)
Summary · context
At the femoral neck, teriparatide increased bone mass and improved bone geometric strength in both treatment groups compared to the placebo group, with the response being dose-related.
Summary · context
We evaluated effects of teriparatide (rDNA origin) injection [teriparatide, rhPTH (1-34), TPTD] on hip structure among a subset 558 postmenopausal women enrolled in the Fracture Prevention Trial.
Summary · context
Patients were randomized to once-daily, self-administered subcutaneous injections of placebo (N = 189), teriparatide 20 mug (TPTD20; N = 186), or 40 mug (TPTD40; N = 183) for a median of 20 months.
Report a problemFND-1587831809
04HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, other teriparatide effects at the femoral shaft did not reach statistical significance versus placebo.
In plain wordsIn women with osteoporosis, other teriparatide effects at the femoral shaft did not differ significantly from placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeOther femoral shaft structural effects
Study
n = 558
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 and 40 mug daily · subcutaneous · Median 20 monthsAs given in this study (human).
Source sentences
Summary
Except for an inconsequential (1%) improvement in section modulus in TPTD20, teriparatide effects did not reach significance at the femoral shaft.
2 context sentences(design, population, supporting numbers)
Summary · context
We evaluated effects of teriparatide (rDNA origin) injection [teriparatide, rhPTH (1-34), TPTD] on hip structure among a subset 558 postmenopausal women enrolled in the Fracture Prevention Trial.
Summary · context
Patients were randomized to once-daily, self-administered subcutaneous injections of placebo (N = 189), teriparatide 20 mug (TPTD20; N = 186), or 40 mug (TPTD40; N = 183) for a median of 20 months.
Report a problemFND-1587831811
05HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide 20 mug increased femoral neck cross-sectional area by 3.5% versus placebo.
In plain wordsIn women with osteoporosis, teriparatide 20 mug increased femoral neck cross-sectional area versus placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck cross-sectional area
Study
n = 375
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 mug daily · subcutaneous · Median 20 monthsAs given in this study (human).
Measurements
CSA mean difference
3.5%
TPTD20 versus placebo
95% CI lower
1.8%
CSA
95% CI upper
5.3%
CSA
Source sentences
Summary
The mean difference (95% CI) in bone cross-sectional area (CSA) in the TPTD20 was 3.5% (1.8% to 5.3%), and 6.3% (4.5% to 8.2%) in TPTD40 at study termination, compared to placebo controls.
2 context sentences(design, population, supporting numbers)
Summary · context
We evaluated effects of teriparatide (rDNA origin) injection [teriparatide, rhPTH (1-34), TPTD] on hip structure among a subset 558 postmenopausal women enrolled in the Fracture Prevention Trial.
Summary · context
Patients were randomized to once-daily, self-administered subcutaneous injections of placebo (N = 189), teriparatide 20 mug (TPTD20; N = 186), or 40 mug (TPTD40; N = 183) for a median of 20 months.
Report a problemFND-1587831803
06HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide 20 mug increased femoral neck section modulus by 3.6% versus placebo.
In plain wordsIn women with osteoporosis, teriparatide 20 mug increased femoral neck bending strength versus placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck section modulus
Study
n = 375
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 mug daily · subcutaneous · Median 20 monthsAs given in this study (human).
Measurements
Section modulus mean difference
3.6%
TPTD20 versus placebo
95% CI lower
1.4%
Section modulus
95% CI upper
5.8%
Section modulus
Source sentences
Summary
Teriparatide treatment increased bending strength, with the mean difference in section modulus being 3.6% (1.4% to 5.8%) and 6.8% (4.6% to 9.1%) greater in the TPTD20 and TPTD40 groups, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
We evaluated effects of teriparatide (rDNA origin) injection [teriparatide, rhPTH (1-34), TPTD] on hip structure among a subset 558 postmenopausal women enrolled in the Fracture Prevention Trial.
Summary · context
Patients were randomized to once-daily, self-administered subcutaneous injections of placebo (N = 189), teriparatide 20 mug (TPTD20; N = 186), or 40 mug (TPTD40; N = 183) for a median of 20 months.
Report a problemFND-1587831805
07HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide 20 mug decreased femoral neck buckling ratio by 5.5% versus placebo.
In plain wordsIn women with osteoporosis, teriparatide 20 mug decreased femoral neck cortical instability versus placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseFemoral neck buckling ratio
Study
n = 375
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 mug daily · subcutaneous · Median 20 monthsAs given in this study (human).
Measurements
Buckling ratio reduction
5.5%
TPTD20 versus placebo
95% CI lower
3.5%
Buckling ratio reduction
95% CI upper
7.5%
Buckling ratio reduction
Source sentences
Summary
Compared to placebo, local cortical instability characterized by the buckling ratio decreased by 5.5% (3.5% to 7.5%) and 8.6% (6.6% to 10.5%) in the TPTD20 and TPTD40 groups, respectively, during the study period.
2 context sentences(design, population, supporting numbers)
Summary · context
We evaluated effects of teriparatide (rDNA origin) injection [teriparatide, rhPTH (1-34), TPTD] on hip structure among a subset 558 postmenopausal women enrolled in the Fracture Prevention Trial.
Summary · context
Patients were randomized to once-daily, self-administered subcutaneous injections of placebo (N = 189), teriparatide 20 mug (TPTD20; N = 186), or 40 mug (TPTD40; N = 183) for a median of 20 months.
Report a problemFND-1587831807
08HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide 20 mug produced an inconsequential 1% improvement in femoral shaft section modulus versus placebo.
In plain wordsIn women with osteoporosis, teriparatide 20 mug produced a small improvement in femoral shaft section modulus versus placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral shaft section modulus
Study
n = 375
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 mug daily · subcutaneous · Median 20 monthsAs given in this study (human).
Measurements
Section modulus improvement
1%
TPTD20 femoral shaft
Source sentences
Summary
Except for an inconsequential (1%) improvement in section modulus in TPTD20, teriparatide effects did not reach significance at the femoral shaft.
2 context sentences(design, population, supporting numbers)
Summary · context
We evaluated effects of teriparatide (rDNA origin) injection [teriparatide, rhPTH (1-34), TPTD] on hip structure among a subset 558 postmenopausal women enrolled in the Fracture Prevention Trial.
Summary · context
Patients were randomized to once-daily, self-administered subcutaneous injections of placebo (N = 189), teriparatide 20 mug (TPTD20; N = 186), or 40 mug (TPTD40; N = 183) for a median of 20 months.
Report a problemFND-1587831810
09HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide 40 mug increased femoral neck cross-sectional area by 6.3% versus placebo.
In plain wordsIn women with osteoporosis, teriparatide 40 mug increased femoral neck cross-sectional area versus placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck cross-sectional area
Study
n = 372
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 mug daily · subcutaneous · Median 20 monthsAs given in this study (human).
Measurements
CSA mean difference
6.3%
TPTD40 versus placebo
95% CI lower
4.5%
CSA
95% CI upper
8.2%
CSA
Source sentences
Summary
The mean difference (95% CI) in bone cross-sectional area (CSA) in the TPTD20 was 3.5% (1.8% to 5.3%), and 6.3% (4.5% to 8.2%) in TPTD40 at study termination, compared to placebo controls.
2 context sentences(design, population, supporting numbers)
Summary · context
We evaluated effects of teriparatide (rDNA origin) injection [teriparatide, rhPTH (1-34), TPTD] on hip structure among a subset 558 postmenopausal women enrolled in the Fracture Prevention Trial.
Summary · context
Patients were randomized to once-daily, self-administered subcutaneous injections of placebo (N = 189), teriparatide 20 mug (TPTD20; N = 186), or 40 mug (TPTD40; N = 183) for a median of 20 months.
Report a problemFND-1587831804
10HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide 40 mug increased femoral neck section modulus by 6.8% versus placebo.
In plain wordsIn women with osteoporosis, teriparatide 40 mug increased femoral neck bending strength versus placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck section modulus
Study
n = 372
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 mug daily · subcutaneous · Median 20 monthsAs given in this study (human).
Measurements
Section modulus mean difference
6.8%
TPTD40 versus placebo
95% CI lower
4.6%
Section modulus
95% CI upper
9.1%
Section modulus
Source sentences
Summary
Teriparatide treatment increased bending strength, with the mean difference in section modulus being 3.6% (1.4% to 5.8%) and 6.8% (4.6% to 9.1%) greater in the TPTD20 and TPTD40 groups, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
We evaluated effects of teriparatide (rDNA origin) injection [teriparatide, rhPTH (1-34), TPTD] on hip structure among a subset 558 postmenopausal women enrolled in the Fracture Prevention Trial.
Summary · context
Patients were randomized to once-daily, self-administered subcutaneous injections of placebo (N = 189), teriparatide 20 mug (TPTD20; N = 186), or 40 mug (TPTD40; N = 183) for a median of 20 months.
Report a problemFND-1587831806
11HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide 40 mug decreased femoral neck buckling ratio by 8.6% versus placebo.
In plain wordsIn women with osteoporosis, teriparatide 40 mug decreased femoral neck cortical instability versus placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseFemoral neck buckling ratio
Study
n = 372
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 mug daily · subcutaneous · Median 20 monthsAs given in this study (human).
Measurements
Buckling ratio reduction
8.6%
TPTD40 versus placebo
95% CI lower
6.6%
Buckling ratio reduction
95% CI upper
10.5%
Buckling ratio reduction
Source sentences
Summary
Compared to placebo, local cortical instability characterized by the buckling ratio decreased by 5.5% (3.5% to 7.5%) and 8.6% (6.6% to 10.5%) in the TPTD20 and TPTD40 groups, respectively, during the study period.
2 context sentences(design, population, supporting numbers)
Summary · context
We evaluated effects of teriparatide (rDNA origin) injection [teriparatide, rhPTH (1-34), TPTD] on hip structure among a subset 558 postmenopausal women enrolled in the Fracture Prevention Trial.
Summary · context
Patients were randomized to once-daily, self-administered subcutaneous injections of placebo (N = 189), teriparatide 20 mug (TPTD20; N = 186), or 40 mug (TPTD40; N = 183) for a median of 20 months.
Report a problemFND-1587831808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.